Forex Analysis & Reviews: 23.07.2025 - Trump strikes deal with...

23.07.2025 01:14 PM

Trump strikes deal with Japan — and other key headlines shaping your portfolio

Open trading account Open demo account

Markets are bracing for a new wave of disruption: Trump seals a tariff deal with Japan, Apple dodges multimillion-dollar fines, Amazon challenges Meta and OpenAI, and AstraZeneca builds a pharma empire in the US amid rising trade barriers. Everything you need to know about the latest deals, market moves, and trading opportunities — in this roundup.

Trump, Japan reach deal: tariffs cut, markets react

The US and Japan have signed a tariff agreement, halting the threat of 25% import duties and locking them in at 15%. The decision triggered a sharp reaction in global markets: the Nikkei surged, the yen swung wildly, and investors rushed to revise their outlooks for Japanese assets. This piece covers the deal's key terms, expert analysis, prospects for Japanese markets and the yen, and actionable trader strategies in the new tariff reality.

Donald Trump once again dominated headlines, defusing one of the most volatile flashpoints of the year — the tariff standoff with Japan. Markets had been bracing for fresh escalation by August 1, with the US threatening to slap 25% tariffs on Japanese imports.

However, a marathon negotiation ended with a deal capping duties at a more manageable 15%. The two sides also agreed on a sweeping package of mutual concessions: Japan pledged to open its auto market to US vehicles without extra technical barriers, ramp up rice, corn, and other agricultural imports worth billions, and join major infrastructure initiatives led by Washington.

The most eye-catching feature of the deal: a $550 billion sovereign investment fund Japan will direct into the US economy, with most of the returns earmarked for American coffers.

In return, Washington agreed to impose minimal tariffs on Japanese semiconductors and pharmaceuticals, and promised that Tokyo would be spared from the harshest trade measures reserved for other US partners.

Markets breathed a sigh of relief: the Nikkei 225 jumped 3.2%, with auto stocks — Toyota, Honda, Mazda — rallying sharply after weeks of pressure tied to looming US tariffs. The yen briefly strengthened to 146.18 per dollar before quickly returning to its previous range.

S&P 500 futures rose slightly, with investors reading the deal as a crucial de-escalation signal for global markets: the biggest tariff threat is off the table, at least for now.

Still, analysts remain cautious. Many see the 15% tariff cap as merely a temporary reprieve for Japanese exporters. Profit margins remain under strain, and for most firms, the relief may be short-lived.

In currency markets, the yen's rally faded quickly, and the anticipated surge in Japanese investment into the US could, over time, put further pressure on Japan's currency.

On the equity side, the Nikkei spike and auto stock rally were a logical response to the lifted tariff threat, but much of that optimism may already be priced in. Going forward, market performance will hinge on how investors digest the deal's fine print and whether those terms translate into real earnings gains.

Many experts now view the US-Japan agreement as a blueprint for other Asian exporters, but the broader outlook remains cautious. Challenges lie ahead for both the yen and Japan's equity indices.

For traders, near-term strategies should focus on volatility. The yen offers short-term speculative opportunities — quick trades on sharp moves tied to news flow.

For Japanese equities and exporters, a moderately bullish bias is advised, with a focus on locking in profits as the post-deal momentum fades. US indices, meanwhile, remain a safer play for conservative strategies, especially in sectors set to benefit from incoming investment flows.

Apple dodges fines as App Store rules bend to Brussels' demands

Apple has once again found itself at the heart of a European antitrust standoff. This time, however, the US tech giant has sidestepped the worst-case scenario. According to insider reports, a strategic overhaul of App Store rules has all but secured EU approval, effectively shielding Apple from daily multimillion-euro fines. Today we break down how Apple outmaneuvered Brussels regulators, what is next for the company, and what traders should be watching closely in the near term.

It all began when the European Commission fined Apple €500 million this spring, accusing the company of barring developers from directing users to alternative payment methods, a violation of the Digital Markets Act (DMA).

Brussels then gave Apple just 60 days to fix the issue: either amend its rules or face daily penalties of up to 5% of global revenue—translating to potential losses of around €50 million per day. In response, Apple was forced to urgently revise its App Store policies and rethink its monetization model to avoid further sanctions.

The new terms for developers are starkly different: Apple's commission on in-app purchases remains at 20% (dropping as low as 13% for smaller studios), but even for external payments, Apple will still take a cut—between 5% and 15%. The most significant shift? Link freedom. Developers are now officially allowed to include as many links to outside payment platforms as they like—previously a strict no-go. It is a direct result of EU pressure to "de-monopolize" the digital space and push for fairer competition in the Big Tech arena.

Markets, it must be said, took the news in stride. Neither Apple's stock nor its reputation showed signs of distress. Investors have grown accustomed to headline clashes between tech giants and European regulators and understand that "business as usual" is no longer the norm for any player.

Formal EU approval is expected in the coming weeks, though Brussels reserves the right to attach further conditions. Apple, for its part, has voiced frustration, arguing that these measures constrain the App Store's business model and force compromise under regulatory duress.

But the most intriguing aspect lies in what comes next. The era of unchecked freedom for US tech companies in Europe is drawing to a close, and Apple is just the first in a series of regulatory showdowns. That means more volatility, as well as more curveballs, for the market.

Traders should pay close attention to Apple's price action and to how other tech names respond. Each new regulatory decision has the potential to shift the balance of power sharply, impacting both individual stocks and broader sector indices.

What's the move? In the coming weeks, trading strategies focused on Apple and tech-sector volatility will remain relevant. Use sharp price swings for tactical trades, while long-term investors should scale in cautiously, with a sharp eye on regulatory risk.

To stay ahead in the tech race, open an account with InstaForex, download our mobile app, and keep your finger on the pulse of the market.

Amazon acquires Bee startup to enter affordable wearable AI assistant market

Amazon has announced the acquisition of Bee, a San Francisco-based startup that developed a $49.99 wearable AI assistant. In this article, we explore what makes the new gadget unique, why Amazon wants it, how the deal reshapes the tech landscape, and why traders should be eyeing Amazon stock amid a new wave of AI momentum.

Amazon is making a bold push to the front of the AI race by acquiring Bee, the startup behind the Pioneer wearable AI assistant priced at just $49.99. Instead of cautiously dipping its toes into wearable AI, Amazon has seized what's already being hailed as the most successful device in its class.

The new bracelet discreetly records and transcribes every word the user says, instantly converting conversations into to-do lists, reminders, and personal reports — all synced with calendars and email.

This acquisition does not just mark Amazon's entry into wearable AI — it's a direct challenge to Meta and OpenAI, pushing the competition to an entirely new level.

Bee co-founder Maria de Lourdes Zollo called the move under Amazon's wing a chance to scale the team's ambitions globally. All Bee employees have been invited to join Amazon. While the deal amount remains undisclosed, Bee has raised just $8.5 million to secure its place in the smart device space, offering a lower-cost alternative to Meta's Ray-Ban smart glasses, which retail at six times the price.

But it's not just about cost. Bee offers up to a week of battery life, comes in bracelet or clip-on form, and uses dual microphones to capture speech even in noisy environments. Industry reviewers already consider Bee the most successful wearable AI device currently available.

Still, the innovation comes with trade-offs — namely, privacy. Bee had previously prided itself on not storing original audio and performing encrypted processing on-device. Now, as part of Amazon's vast data ecosystem, it remains to be seen whether those standards will hold. Amazon insists that data protection and user transparency remain top priorities, but it stops short of fully committing to Bee's previous privacy policies.

This acquisition is more than just a product expansion for Amazon. It sends a clear message: the age of "hardware for hardware's sake" is fading, and personalized, deeply integrated AI is taking center stage — especially within the Alexa ecosystem, where Bee could become the next big hit.

Amid reports of OpenAI's $6.5 billion deal with Jony Ive and Meta's multibillion-dollar partnership with EssilorLuxottica, Amazon is not content to sit on the sidelines. Bee has not even officially launched — the public release is scheduled for September — giving Amazon the opportunity to turn a still-developing startup into the market's next breakout story.

For traders, this is not just a headline — it is a call to action. Amazon's stock, along with shares of other wearable AI players, warrants close attention. In the short term, such deals can drive volatility and investor interest. In the long term, they could spark sustained growth across the entire segment.

The recommendation is simple: stay alert to market news, consider opening positions in Amazon on expectations of further AI expansion, and do not miss the chance to lock in gains amid market swings.

AstraZeneca pours $50 billion into US market push

This week, AstraZeneca stunned the market with a pledge to invest $50 billion into US manufacturing and R&D by 2030. The British-Swedish pharma giant appears to be bracing for Trump's tariff barrage and the new rules of the game. In this article, we break down why the company is making its move now, what the risks are for the sector, and how traders can capitalize on the shift.

AstraZeneca is moving preemptively, announcing a $50 billion investment in US-based manufacturing and research through the end of the decade.

Against the backdrop of Donald Trump's protectionist rhetoric and looming tariffs that could shake the global pharma industry, AstraZeneca is betting on the American market. The company plans to build the largest plant in its history in Virginia, producing cutting-edge treatments for chronic illnesses, including next-gen weight control and cholesterol-lowering drugs.

This move is more than a response to "America First" — it is an attempt to turn tariff threats into a growth engine. New trade realities are forcing pharma giants to relocate production to the US, cut prices for domestic consumers, and pour capital into innovation to survive and thrive amid escalating trade tensions.

Unwilling to be held hostage by policy swings, AstraZeneca is doubling down on automation, artificial intelligence, and development of novel GLP-1 and PCSK9 molecules. It is also expanding its portfolio across metabolic disorders, oncology, and rare diseases.

The US already accounts for over 40% of AstraZeneca's revenue. The new goal is to push that figure to 50% and hit $80 billion in annual sales by the end of the decade.

But here's the catch: AstraZeneca is not alone. Pharma heavyweights Roche, Eli Lilly, Johnson & Johnson, Novartis, and Sanofi are all launching similar megaprojects, while European and Indian factories scramble to ship as much inventory as possible to the US ahead of new tariffs.

This race will have casualties. Generics and medical devices — about half of which are imported into the US — could face price shocks and supply disruptions, creating fertile ground for record volatility in the pharma sector.

But where there is risk, there is opportunity. For traders, America's pharma boom is a clear window for profit. AstraZeneca shares could outperform, buoyed by progress in its GLP-1 pipeline. Its new drug candidate, AZD5004, acquired from Eccogene for $185 million, is already showing promising clinical results.

Against this backdrop, AstraZeneca's strategic expansion in the US only strengthens its competitive edge and boosts investor interest in the stock.

The smart play is to keep close tabs on sector news and seize speculative surges from pharma rallies. Do not overlook the long-term potential of a supply-chain overhaul that could transform the entire healthcare landscape.

To take advantage of this strategic shift in real time, open a trading account with InstaForex and install our mobile app. You will gain instant access to AstraZeneca's stock dynamics, as well as those of other global pharmaceutical giants. You will also receive unlimited tools to act on the most lucrative ideas, without limits!